Fleishman Hillard Release: Study Establishes Safety and Clinical Benefit of SIR-Spheres® Microspheres in Treating Metastatic Liver Tumors in Patients who Failed Systemic Chemotherapy
3/27/2012 10:17:53 AM
SAN FRANCISCO--(BUSINESS WIRE)--SIR-Spheres® microspheres are safe and provide clinical benefit for patients with colon cancer liver metastases who have previously received liver-directed and systemic chemotherapy, according to the results of a prospective clinical study announced today at the Society of Interventional Radiology’s 37th Annual Scientific Meeting. The data were presented by the interventional investigator Constantinos T. Sofocleous, M.D., in collaboration with Nancy Kemeny, M.D., GI Medical Oncologist from Memorial Sloan-Kettering Cancer Center in New York. SIR-Spheres microspheres are manufactured by Sirtex, a leading developer of targeted, innovative liver cancer therapies.